International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.10003044
Original Article
Assessment of frailty in Liver Cirrhosis: A Western Indian Experience
 ,
 ,
 ,
 ,
 ,
 ,
Published
Oct. 14, 2023
Abstract

Background & Aim: Frailty is a major prognostic factor in cirrhosis. Its assessment and intervention towards performance enhancement is important in the management of cirrhosis. Our study aimed to assess the prevalence of frailty in patients with cirrhosis and comparison of frailty by different indices.

Methods: One hundred and twenty cirrhotic patients were included. Frailty assessment was done using compares Fried frailty index (FFI), Clinical frailty index (CFI), Short physical performance battery (SPPB), Edmonton frail scale (EFS), Liver Frailty Index (LFI), ECOG, Karnofsky performance scale (KPS), and Instrumental activity of daily living (IADL). Risk factors of frailty analysis were made based on LFI.

Results: Mean age of presentation was 43.57±10.16years, and 80% were males. Most common etiology was alcohol (50.1%). Prevalence of frailty based on LFI, FFI, CFI, SPPB, EFS, ECOG, KPS, and IADL was 45%, 38.3%, 39.2%, 46.7%, 45%, 36.7%, 36.7%, and 29.2%. There was a significant positive association of frailty based on the LFI score with other scores (P<0.0001). Risk factors for frailty were being underweight (50% vs. 15%; P<0.0001), severity of ascites (P<0.0001), CTP score (P<0.0001), Mean MELD score (18.33±4.33 vs. 14.37±3.49; P<0.001) and MELD Na (20.43±4.62 vs. 15.50±3.95; P<0.001) was significantly higher among frails compared to non-frail patients.

Conclusions: Frailty is quite prevalent in liver cirrhosis. Frailty assessment should be routinely carried out. Frailty assessment by any score can be used to prevent further complications in these patients.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
809 Views
31 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved